

Supplementary Table I. Characteristics at baseline for non-randomised patients (n=96)

	Non-randomised patients TCZ+MTX
<i>Demographics and disease characteristics</i>	
Women	76 (79.2)
Age, years	52.3 (13.2)
Disease duration, years	7.5 (9.5)
<i>Clinical outcomes</i>	
DAS28	6.1 (1.2)
CDAI	36.24 (12.09)
SDAI	47.76 (19.86)
SJC (0-28 scale)	9.6 (5.4)
TJC (0-28 scale)	13.0 (6.9)
CRP (mg/dl) in range	50 (52.1)
ESR (mm/h) in range	34 (35.4)
PDGA (0-100 VAS scale)	71.4 (21.1)
MDGA (0-100 VAS scale)	64.3 (16.4)
<i>Patient-reported outcomes</i>	
HAQ*	1.6 (0.7)
SF-12 Mental health component [‡]	40.9 (13.1)
SF-12 Physical health component [‡]	27.5 (7.2)

Data are mean (SD) or n (%).

CDAI: clinical disease activity index; CRP: C-reactive protein; DAS28: disease activity score 28; ESR: erythrocyte sedimentation rate; HAQ: health assessment questionnaire; MDGA: physician's global assessment of disease; MTX: methotrexate; PDGA: patient's global assessment of disease; SDAI: simple disease activity index; SJC: swollen joint count; TJC: tender joint count; TCZ: tocilizumab.

*Lower score denotes less functional disability.

[‡]Higher score denotes better physical and mental quality of life.